Cognition Therapeutics Inc. (CGTX)
NASDAQ (CM) NASDAQ (CM) Primary 
Cognition Therapeutics, Inc. (CGTX) Q4 2025 Earnings Call Transcript
Cognition Therapeutics, Inc. (CGTX) Q4 2025 Earnings Call Transcript
Cognition Therapeutics (CGTX) Moves to Buy: Rationale Behind the Upgrade
Cognition Therapeutics (CGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cognition: Zervimesine AD Treatment Program FDA Alignment Means "Strong Buy" Rating
I rate Cognition Therapeutics a "Strong Buy" due to FDA alignment on two pivotal phase 3 trials zervimesine in mild-to-moderate Alzheimer's patients with low p-tau217; Successful results means NDA filing. Zervimesine showed a remarkable 95% slowing of cognitive decline in the low-ptau217 biomarker-defined subgroup, supporting a precision medicine approach and strong phase 3 prospects. The company is well-financed through government grants and has multiple funding options, with operational funding into Q2 2026, reducing near-term dilution risk.
Cognition Therapeutics, Inc (CGTX) Q4 2024 Earnings Call Transcript
Cognition Therapeutics, Inc (NASDAQ:CGTX ) Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET Company Participants Mike Moyer - LifeSci Advisors Lisa Ricciardi - Chief Executive Officer John Doyle - Chief Financial Officer Anthony Caggiano - Chief Medical Officer, Head of R&D Conference Call Participants Mayank Mamtani - B. Riley Securities Daniil Gataulin - Chardan Operator Greetings, and welcome to the Cognition Therapeutics Fourth Quarter and Full Year 2024 Earnings Call.
Why Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday?
Cognition Therapeutics, Inc. CGTX revealed positive results from the exploratory Phase 2 SHIMMER study demonstrating that CT1812 produced strong therapeutic responses across behavioral, functional, cognitive and movement measures in patients with dementia with Lewy bodies (DLB).
Cognition Therapeutics (CGTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Cognition Therapeutics (CGTX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Cognition Therapeutics, Inc. (CGTX) Q1 2024 Earnings Call Transcript
Cognition Therapeutics, Inc. (NASDAQ:CGTX ) Q2 2024 Earnings Conference Call August 11, 2024 8:30 AM ET Company Participants Thomas Johnson - Director, Corporate Communications, LifeSci Advisors, LLC Lisa Ricciardi - Chief Executive Officer John Doyle - Chief Financial Officer Anthony Caggiano - Chief Medical Officer, Head of R&D Conference Call Participants Charles Duncan - Cantor Fitzgerald Raghuram Selvaraju - H.C. Wainwright Daniil Gataulin - Chardan Operator Hello, and thank you for standing by.
Why Is Cognition Therapeutics (CGTX) Stock Down 33% Today?
Cognition Therapeutics (NASDAQ: CGTX ) stock is falling hard on Monday after the clinical-stage biopharmaceutical company provided results from its proof-of-concept Phase 2 ‘SHINE' study. This study evaluated the effectiveness of treating patients with CT1812.
